Foghorn Therapeutics reports Phase 1 data for FHD-286 in uveal melanoma, will not advance independently

Foghorn Therapeutics Inc.

Phase 1 dose escalation study of FHD-286 in 73 metastatic uveal melanoma patients showed safety and tolerability; most common adverse events were dysgeusia, fatigue, AST increase.
One patient achieved durable partial response (>16 months on treatment), nine patients had stable disease, and tumor reductions were observed in eight patients.
Company will not advance FHD-286 in uveal melanoma; plans to initiate combination study with decitabine or cytarabine in relapsed/refractory AML in Q3 2023.
Preliminary immune modulation markers in tumor microenvironment support combination with checkpoint inhibitors; full results to be presented at future scientific meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.